Navigation Links
Second annual Brain Tumor Biotech Summit 2013 at Weill Cornell
Date:6/7/2013

NEW YORK (June 7, 2013) -- The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.

"Regardless of our backgrounds, our shared vision and purpose today was to bridge the gap between basic and clinical science," says Dr. John Boockvar, chair of the Summit, director of the Brain Tumor Research Group, professor of neurological surgery at Weill Cornell Medical College and a neurosurgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "It often takes decades to realize discoveries from bench to bedside when it needs to be a few years. This dynamic meeting advanced collaborations vital to accelerating the translation of new scientific findings into novel therapeutics that can be delivered rapidly to our patients."

More than 23,000 people in the United States will be diagnosed with brain or spinal tumors this year and more than 14,000 patients will succumb to their disease, according to the American Cancer Society. With the patient median survival rate of 15 months, there is a crucial need to identify more effective treatments for brain tumors that will not only extend life, but also lead to potential cures.

"Brain cancer touches the lives of thousands of families a year, and it is incumbent upon us to devise novel treatments and therapeutics that will better target malignant tumors and enhance human health," adds Dr. Lewis Cantley, the Margaret and Herman Sokol Professor in Oncology Research and professor of cancer biology in medicine at Weill Cornell and director of the Cancer Center at Weill Cornell and NewYork-Presbyterian Hospital. "However, as federal funding for research has plummeted -- hastened under sequestration -- it is become more important than ever for brain tumor researchers to supplement their government grants with private funding to advance their research."

Industry leaders from the biotech industry, venture capital firms, finance, non-profit foundations and pharmaceutical companies participated in the Brain Tumor Biotech Summit discussions regarding ways to get new research findings noticed and funded. Top brain tumor researchers from across the country presented their latest advances in vaccine treatments, nanotechnology, stem cell biology, angiogenesis, gene therapy, targeted therapeutics, novel medical devices and a host of other topics relevant to the diagnosis and treatment of human cancer.

"The Brain Tumor Biotech Summit is the only place that interfaces scientists, clinicians, financial investors and the biotech industry. I know of no other place that brings those four groups together," says Franklin Berger, a leading biotech industry expert and moderator of the "VC Roundtable: How to Get Your Research or Company Noticed? Lessons from the Investment Experts" panel discussion at the Summit. "That's critical because the cost and time required to get a therapy across the finish line, from thought to vial, is longer and more complex than ever."

The Summit also represents a new way to engage academia, industry and investors in collaborative research. Not only are experts at Weill Cornell adopting the approach for other key areas of neurosurgery, including concussion, spinal cord injury and stroke, but other institutions are also replicating the format to spur research within their own facilities.

"The Summit is an amalgamation of thought leaders in the areas of science, industry and venture capital who collectively have already expanded the boundaries in brain tumor research, leading to novel ideas and new clinical trials. This year's Summit forged new, game-changing relationships, and I'm excited to see the advancements in brain tumor treatments that will be catalyzed as a result," says Dr. Philip E. Stieg, professor and chairman of neurological surgery at Weill Cornell Medical College and neurosurgeon-in-chief at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.


'/>"/>

Contact: Gerard Farrell
gerard.farrell@hkstrategies.com
212-885-0487
Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Minnesota Becomes the Second State to Pass a Homeowners Bill of Rights
2. Secondhand smoke causes longer hospitalization in infants with respiratory infections
3. Reclaim Skin's Youth in 60 Seconds with Bi-Matrix™
4. Natures Best Cleaners in Sunnyvale Open Second Location in Fremont
5. eHealthcare Solutions Hosts Second Annual Publisher Summit
6. Schimenti and Boston University Take A Second Look at Construction Cameras
7. National Mobility Awareness Month Strives to Create Awareness for the Second Year
8. Sandbridge Virginia Beach Real Estate Sales Improve and Becoming A Big Draw for Second Home Investors
9. Magnetic bracelet relieves pain in seconds announces Superior Magnetics
10. Second-generation TAVI device -- Lotus Valve -- shows good performance in REPRISE II
11. San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology: